SBIR/STTR Award attributes
Epigenetic changes in DNA methylation pattern can result due to aging, diseases, or environmental changes and have been identified as biomarkers for several neuropsychiatric and neurodegenerative disorders, cancer, traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). As a result, DNA methylation signatures are being explored to assist with disease diagnosis, monitoring disease progression, and determining treatment efficacy. Current DNA methylation detection instrumentation, however, suffer from several intrinsic drawbacks including time consuming and labor-intensive sample preparation, bulky equipment, and susceptibility to contamination due to manual sample handling. We propose to develop a novel microfluidic platform for detection and quantification of DNA methylation status from clinically relevant samples. Phase I will develop the individual microfluidic modules for DNA extraction, amplification and detection and establish a proof-of-concept for the platform. Phase II activities will focus on development of a disposable integrated microfluidic cartridge and a durable instrument, including extensive testing and validation activities using clinically relevant samples.
